Adjuvance Technologies Inc
CAGE Code: 5NFJ7
NCAGE Code: 5NFJ7
Status: Active
Type: Manufacturer
Dun & Bradstreet (DUNS): 831676247
Summary
Adjuvance Technologies Inc is an Active Manufacturer with the Cage Code 5NFJ7 and is tracked by Dun & Bradstreet under DUNS Number 831676247..
Address
2900 S 70Th St Ste 130
Lincoln NE 68506-3733
United States
Points of Contact
No Points of Contact...
Related Information
People who viewed this 'CAGE Code' also viewed...
Gold Coast Digital Stepfamily Assn Of America Inc Brooks Rodney Balfour L G Co Inc Moll James Jr Painting Racom Corp Cases Plus, Inc. Ransomes America Corp Nebraska Neon Sign Co Linweld Inc Lincoln Mfg Co Insupco Heinke Technology Inc. Top Notch Products Inc University Of Nebraska Dept Of Prosynergy Llc Sandvik Inc Metalworking Products Nebraska Boiler Co Inc Petticoat Construction Inc. Nebraska Trucking Foundation, Inc
Frequently Asked Questions (FAQ) for CAGE 5NFJ7
- What is CAGE Code 5NFJ7?
- 5NFJ7 is the unique identifier used by NATO Organizations to reference the physical entity known as Adjuvance Technologies Inc located at 2900 S 70Th St Ste 130, Lincoln NE 68506-3733, United States.
- Who is CAGE Code 5NFJ7?
- 5NFJ7 refers to Adjuvance Technologies Inc located at 2900 S 70Th St Ste 130, Lincoln NE 68506-3733, United States.
- Where is CAGE Code 5NFJ7 Located?
- CAGE Code 5NFJ7 is located in Lincoln, NE, USA.
Contracting History for CAGE 5NFJ7 Most Recent 25 Records
- 75N93019C00016
- Igf::Ot::Igf Preclinical Development Of Semisynthetic Saponin Immunological Adjuvant Titerquil-1055 In The Context Of An Influenza Vaccine. New Award
- 12 Jun 2019
- Igf::Ot::Igf Preclinical Development Of Semisynthetic Saponin Immunological Adjuvant Titerquil-1055 In The Context Of An Influenza Vaccine. New Award
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,471,319.00
- Department Of Health And Human Services (Hhs)
- HHSN272201700066C
- Igf::Ot::Igf Determining The Impact Of Semisynthetic Saponin Immunologic Adjuvant Titerquil-1055 On Influenza Vaccine Immunogenicity And Stability
- 31 Jul 2017
- Igf::Ot::Igf Determining The Impact Of Semisynthetic Saponin Immunologic Adjuvant Titerquil-1055 On Influenza Vaccine Immunogenicity And Stability
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $223,002.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00016
- Preclinical Development Of Semisynthetic Saponin Immunological Adjuvant Titerquil-1055 In The Context Of An Influenza Vaccine.
- 12 May 2020
- Preclinical Development Of Semisynthetic Saponin Immunological Adjuvant Titerquil-1055 In The Context Of An Influenza Vaccine.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,471,319.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00016
- Incorporate The Change Order And Provided Funds In The Amount Of $899,905.
- 2 Aug 2019
- Incorporate The Change Order And Provided Funds In The Amount Of $899,905.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,471,319.00
- Department Of Health And Human Services (Hhs)